17.87
2.88%
-0.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$18.40
Aprire:
$18.02
Volume 24 ore:
6.77M
Relative Volume:
2.34
Capitalizzazione di mercato:
$13.18B
Reddito:
$956.00K
Utile/perdita netta:
$-196.68M
Rapporto P/E:
-10.63
EPS:
-1.6811
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
+0.22%
1M Prestazione:
-4.03%
6M Prestazione:
+129.10%
1 anno Prestazione:
+636.91%
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.87 | 13.18B | 956.00K | -196.68M | -113.02M | -0.24 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-11 | Iniziato | Wells Fargo | Overweight |
2024-12-06 | Iniziato | Jefferies | Buy |
2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
2024-08-12 | Iniziato | H.C. Wainwright | Buy |
2024-05-07 | Iniziato | Citigroup | Buy |
2024-03-26 | Iniziato | Stifel | Buy |
2018-06-28 | Downgrade | Janney | Buy → Neutral |
2018-05-02 | Iniziato | Janney | Buy |
2018-04-12 | Reiterato | Needham | Buy |
2018-02-13 | Iniziato | BTIG Research | Buy |
2018-01-04 | Iniziato | SunTrust | Buy |
2017-12-01 | Ripresa | H.C. Wainwright | Buy |
2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
2016-10-05 | Reiterato | Needham | Buy |
2016-09-16 | Iniziato | H.C. Wainwright | Buy |
2015-03-30 | Iniziato | Needham | Buy |
2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Barclays PLC Lowers Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - Insider Monkey
Why These 10 Stocks Jumped Yesterday - Insider Monkey
Where Will Summit Therapeutics Be in 5 Years? - Yahoo Finance
3 Stocks That Could Turn $1,000 into $5,000 by 2030 - The Motley Fool
Wellington Management Group LLP Has $968,000 Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading Up 6.8%Should You Buy? - MarketBeat
(SMMT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Has Summit Therapeutics Stock Already Peaked? - AOL
State Street Corp Sells 654,623 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday - MSN
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street - Yahoo! Voices
Virtu Financial LLC Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wells Fargo Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - MSN
Summit Therapeutics (NASDAQ:SMMT) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat
Polar Asset Management Partners Inc. Takes Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday - MSN
Bank of Montreal Can Invests $2.04 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
The Manufacturers Life Insurance Company Raises Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Warning: This Skyrocketing Stock Has a Hidden Risk - AOL
Charles Schwab Investment Management Inc. Boosts Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit - Yahoo Finance
Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Acquired by Fmr LLC - MarketBeat
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial - Seeking Alpha
Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Acquired by Baker BROS. Advisors LP - MarketBeat
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher - Yahoo Finance
Cerity Partners LLC Invests $2.18 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
2 Hot Biopharma Stocks to Buy and Hold for 5 Years - AOL
Intech Investment Management LLC Invests $694,000 in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
(SMMT) Investment Analysis and Advice - Stock Traders Daily
Summit Therapeutics to Present at Upcoming Investor Conferences - BioSpace
3 Monster Stocks in the Making - Yahoo Finance
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN
Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright - MarketBeat
(SMMT) Trading Report - Stock Traders Daily
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics - Investor's Business Daily
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga
Is Summit Therapeutics a Millionaire Maker? - AOL
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Zanganeh Mahkam | Chief Executive Officer |
Mar 26 '24 |
Buy |
3.75 |
30,000 |
112,500 |
30,000 |
Zanganeh Mahkam | Chief Executive Officer |
Mar 27 '24 |
Buy |
3.72 |
26,000 |
96,720 |
520,814 |
Dhingra Ankur | Chief Financial Officer |
Mar 26 '24 |
Buy |
3.75 |
100,000 |
375,000 |
354,958 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):